Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

NCT02762006 is registered in ClinicalTrials.gov with Moshe Ornstein as lead sponsor.

NCT NCT02762006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02762006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Lead sponsor
Moshe Ornstein
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2016
Completion date
November 6, 2020
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, renal cell carcinoma